PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

White House officials, Congress members to tour US border facility

Show Me

Arizona Governor Says Kamala Harris Is ‘The Worst Possible Choice’ To Oversee Border Security

Show Me

Biden taps VP Harris to lead response to border challenges

Show Me

Border Patrol holds migrant families for days under a south Texas bridge

Show Me

Border Agent Gives Inside Account of Overcrowded Facilities

Show Me

Rep. Darrell Issa: Border crisis is being contrived, CBP and ICE told to ‘stand down’

Show Me

Biden Team Ignored Warnings from Career Immigration Officials That Their Actions Could Cause a Border Crisis

Show Me

Cruz, 17 Senators to Visit Donna Overflow Facility on Friday Amid Surge in Illegal Immigration

Show Me

Journalists Start Demanding Substack Censor its Writers: to Bar Critiques of Journalists

Show Me

Facebook Looks To Compete In Market Dominated By Homeless Reporters

Show Me

Biggest Casualty of COVID? Personal Freedoms.

Show Me

Glenn Greenwald criticizes ‘corporate journalists’ who seek to censor news they don’t like

Show Me

New cage facility for migrant children underway in Rio Grande Valley

Show Me

Mexican Drug Cartels Use Children as Decoys to Smuggle Criminals Into US, Texas Sheriff Says

Show Me

Border Patrol Holding Thousands of Migrant Children Past The Legal Limit, Some Detained Longer Than 10 Days

Show Me

New Border Photos Show Children Sleeping Shoulder-to-Shoulder in Transparent Pen

Show Me

“Shameful”: Amid Border Emergency, Immigrant Rights Advocates Urge Biden to Stop Detaining Children

Show Me

Biden Administration to Use San Diego Convention Center as Immigration Shelter Amid Surge

Show Me

3 Fully Vaccinated Hawaii Residents Test Positive for COVID-19

Show Me

Senior Fox Business producer dies from coronavirus complications

Show Me

Project Veritas Obtains Photos of Biden’s Migrant Detention Centers

Show Me

Elections Aren’t The Only Thing The Power Structure Rigs | Monsanto & The World Wildlife Fund Sustainability Certificates

Show Me

How It All Started To Crumble | Bayer Discovers “Black Ops” Division Run by Monsanto

Show Me

Revealed: Monsanto predicted crop system would damage US farms

Show Me

Bayer Won’t Ask U.S. Supreme Court to Reverse First Roundup Loss

Show Me

Strawberries, Spinach, Kale Top EWG’s 2021 ‘Dirty Dozen’ List

Show Me

America’s Proxy Wars With Iran Ramp Up | Saudi Navy Starts Drills to Protect Oil Sites as Attacks Mount

Show Me

Upcoming Pentagon report will detail ‘difficult to explain’ UFO sightings

Show Me

Former Trump intel chief says some recorded UFO behaviors defy explanation

Show Me

US has secret evidence of UFOs breaking sound barrier without a sonic boom

Show Me

Poll Shows Overwhelming Majority Support Voter ID Laws

Show Me

Australian Politicians Push Resolution Condemning China’s Abuse of Uyghurs

Show Me

Suspect bashed Asian woman with pipe during NYC attack

Show Me

Asians Rarely, Though Increasingly Face Hate Crimes

Show Me

YouTube Removed Our Lockdown Anniversary Video, Here’s Our Response

Show Me

Pfizer’s COVID Vaccine Could Become Most Lucrative Drug in the World

Show Me

China has detained my young children. I don’t know if I’ll ever see them again

Show Me

DR JOHN LEE: My darkest predictions have come true… the effects of lockdowns are catastrophic

Show Me

Trump’s net worth dropped by $700 million while he took no salary as President

Show Me

With Biden In Office, ISIS Is Rising From The Ashes Worldwide | ISIS Claims Responsibility for Killing 33 Malian Soldiers

Show Me